Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate.
Pfizer executives were warned by one of their own scientists about a potential link between the antidepressant med Zoloft and birth defects, accordingly to a newly surfaced document cited by Bloomberg.
Sterile injectable drugs are a growth area, but they are notoriously tricky to manufacture. Mylan has found that out the hard way and is having to expand a recall of cancer drugs that it began in April because they may contain particulate. Some of the drugs were manufactured for Pfizer.
Pfizer's bid to protect its pain drug Lyrica (pregabalin), which has lost some patent protection in the U.K., has had some unintended side effects.
Specialty drugmaker Swedish Orphan Biovitrum (Sobi) has given the cold shoulder to a potential buyer, that may or may not be Pfizer, who was not giving it the kind of financial appreciation that it believes it deserves. But given the frenetic M&A market, an analyst says it is probably just a matter of time before someone snaps up the orphan drugmaker.
Pfizer's "Get Old" campaign is going in a new direction. The drugmaker's counterintuitive--yet quite successful--aging campaign celebrates turning four with a new look and attitude built around commencing, appropriately timed to the new-graduate season. And it already has older folks taking selfies on the streets of New York.
A move by Takeda Pharmaceutical to consolidate its Vaccine Business Unit into hubs should allow sharper focus on a complex set of vaccine programs covering norovirus, dengue and seasonal influenza in an increasingly competitive global horse race.
Pfizer will send GE biopsy samples for analysis using its MultiOmyx tumor analysis technology and services in a bid to get an upper hand in drug development.
Hospira recalled more than 60 lots of the pain reliever ketorolac tromethamine injection in January because of the potential for crystals in the 18 million vials that had been shipped in the U.S. and Singapore.
Last month, Pfizer announced it had cut short its PALOMA-3 trial thanks to impressive second-line data for new cancer-fighter Ibrance. And now, industry-watchers have a glimpse into those data, announced Saturday at ASCO.